Biota signs licensing agreement with Boehringer Ingelheim

Published: 8-Dec-2006
Regulatory

Australian drug manufacturer Biota will boost its research team following the signing of a A$102m licensing agreement for a proposed Hepatitis C treatment.


Australian drug manufacturer Biota will boost its research team following the signing of a A$102m licensing agreement for a proposed Hepatitis C treatment.

German pharmaceutical company Boehringer Ingelheim bought into the early-stage drug deal in the anticipation of large rewards should it prove a breakthrough treatment for the virus.

Biota managing director Peter Cook said the agreement validated the company's ability consistently to deliver candidate drugs to major pharmaceutical companies.

See more

You may also like

Regulatory

ECHA adds two hazardous chemicals to list of substances of very high concern

Read more
Companies are responsible for managing the risks of these chemicals and giving customers and consumers information on their safe use

Trending Articles

  1. NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant MHRA-approved licences and creating dedicated NHS purchasing arrangements to improve long-term supply resilience
  2. testo Saveris 1 update automates environmental monitoring workflows for pharma compliance Testo Saveris, global leader in measurement solutions, has announced the latest software update for its testo Saveris 1 Environmental Monitoring System, designed to address the evolving needs of the pharmaceutical industry by delivering reliable and precise monitoring of key metrics, including temperature and humidity
  3. ECHA adds two hazardous chemicals to list of substances of very high concern Companies are responsible for managing the risks of these chemicals and giving customers and consumers information on their safe use
  4. FDA accepts first quality control standard for mesenchymal stromal cells The FDA has accepted the first dedicated quality control protocol for mesenchymal stromal cells, recognising the Tasly 3P Characterisation Assay and setting a new regulatory benchmark for MSC safety and clinical performance
  5. En Carta Diagnostics bags FDA Breakthrough Device Designation for EC Pocket Lyme test The rapid, Point-of-Need molecular diagnostic platform will fill a critical gap in early-stage detection of Borrelia bacteria, the cause of Lyme disease

Upcoming event

High Shear = Mixing Success

19 February 2026 | Virtual See all

You may also like

Regulatory

ECHA adds two hazardous chemicals to list of substances of very high concern

Companies are responsible for managing the risks of these chemicals and giving customers and consumers information on their safe use
Regulatory

NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages

NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant MHRA-approved licences and creating dedicated NHS purchasing arrangements to improve long-term supply resilience
Regulatory

En Carta Diagnostics bags FDA Breakthrough Device Designation for EC Pocket Lyme test

The rapid, Point-of-Need molecular diagnostic platform will fill a critical gap in early-stage detection of Borrelia bacteria, the cause of Lyme disease
Regulatory

testo Saveris 1 update automates environmental monitoring workflows for pharma compliance

Testo Saveris, global leader in measurement solutions, has announced the latest software update for its testo Saveris 1 Environmental Monitoring System, designed to address the evolving needs of the pharmaceutical industry by delivering reliable and precise monitoring of key metrics, including temperature and humidity
Regulatory

FDA accepts first quality control standard for mesenchymal stromal cells

The FDA has accepted the first dedicated quality control protocol for mesenchymal stromal cells, recognising the Tasly 3P Characterisation Assay and setting a new regulatory benchmark for MSC safety and clinical performance
Regulatory

3PBIOVIAN secures French CIR certification for Spain and Finland R&D sites

The CDMO has obtained French Crédit d’Impôt Recherche (CIR) certification for its Pamplona and Turku sites, enabling French partners to access tax incentives when collaborating on recombinant protein and advanced therapy projects
Regulatory

Shilpa Medicare targets US approval for extended-release Ondansetron injection for CINV

Shilpa Medicare plans to pursue US approval and licensing partners for OERIS after a Phase III study in India met all primary and secondary endpoints and showed a strong safety profile in chemotherapy-induced nausea and vomiting
Subscribe now